Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane.
Type:
Application
Filed:
September 14, 2023
Publication date:
January 4, 2024
Applicant:
AMNEAL COMPLEX PRODUCTS RESEARCH LLC
Inventors:
Navnit H. Shah, Dipen Desai, Wantanee Phuapradit, Jaydeep Vaghashiya, Kanji Meghpara
Abstract: A method for detecting and influencing an uptake of bioactive substances in a hydrogel material and/or release of bioactive substances from the hydrogel material, wherein the hydrogel material is a polymer network formed from charged and uncharged building blocks, the affinity of which network for bioactive substances is configurable by parameters defining the charged building blocks, and whose electrical charge storage capacity depend on interaction with the hydrogel binding of bioactive substances to the hydrogel material. When the hydrogel material is contacted with a biofluid, a change in electrical resistance and/or a change in charge storage capacity of the hydrogel material is detected. Uptake or a release of bioactive substances from the hydrogel material into the biofluid is determined by change in electrical resistance. The invention further relates to a suitable electrically conductive hydrogel material.
Type:
Application
Filed:
November 11, 2021
Publication date:
January 4, 2024
Applicant:
LEIBNIZ-INSTITUT FÜR POLYMERFORSCHUNG DRESDEN E.V.
Inventors:
Teuku Fawzul Akbar, CHRISTOPH TONDERA, IVAN MINEV, UWE FREUDENBERG, CARSTEN WERNER
Abstract: A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.
Type:
Application
Filed:
September 15, 2023
Publication date:
January 4, 2024
Applicant:
MEDINCELL
Inventors:
Georges GAUDRIAULT, Sylvestre GRIZOT, Mark HURTIG, Matthew SHIVE
Abstract: Disclosed herein are methods of treating an ocular surface disease, disorder, or wound comprising applying an umbilical cord sheet and/or a controlled-release formulation to a tissue or surrounding tissue of an eye of a subject, such as the inferior fornix, superior fornix, and/or cornea. Further disclosed herein are kits for treatment of an ocular surface disease, disorder, or wound comprising the umbilical cord sheet and/or controlled-release formulation and a device for delivering and applying the umbilical cord sheet and/or controlled-release formulation to an eye of a subject.
Type:
Application
Filed:
April 2, 2021
Publication date:
January 4, 2024
Inventors:
Scheffer TSENG, Sean TIGHE, Ek Kia TAN, Jason Eric VEVODA
Abstract: The present disclosure is directed to use of surfactant with fish gelatin based, freeze dried orally disintegrating tablets. Specifically, Applicants discovered that a small amount of surfactant in combination with high molecular weight fish gelatin in a pharmaceutical formulation can ensure good solution/suspension flow into preformed molds during dosing in order that the finished dosage form has an acceptable shape.
Abstract: A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.
Type:
Application
Filed:
August 3, 2023
Publication date:
January 4, 2024
Applicant:
Fertin Pharma A/S
Inventors:
Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen, Kent Albin Nielsen, Rikke Pranger-Rasmussen
Abstract: The present invention relates to inhalable dry powder formulations comprising one or more antibodies or one or more angiogenesis inhibiting active pharmaceutical ingredients, methods of manufacture of such compositions, e.g. via spray drying, as well as their local administration to the lung for use in the treatment, prevention and/or delay of progression of asthma, COPD, lung infections, cystic fibrosis, or lung cancer.
Type:
Application
Filed:
November 17, 2021
Publication date:
January 4, 2024
Applicant:
Lonza Bend Inc.
Inventors:
Kimberly Shepard, Michael Banks, David Vodak
Abstract: The present invention relates to a drug delivery platform. In particular, it relates to a foil-based drug delivery platform for delivery to the intestine.
Type:
Application
Filed:
March 31, 2021
Publication date:
January 4, 2024
Inventors:
Anja Boisen, Lasse Hølund Eklund Thamdrup, Jacob Rune Jørgensen, Thomas Rades, Anette Müllertz, Mahdi Ghavami, Khorshid Kam Guyan
Abstract: An antiviral cannabinoid-containing thermoresponsive sol-gel formulation and its use in the treatment or prevention of viruses such as Coronaviruses. In particular embodiments, the cannabinoid containing thermoresponsive sol-gel formulation is adapted for nasal delivery and comprises a micellar composition comprising a cannabinoid composition having at least 70% cannabidiol (CBD).
Abstract: Compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.
Abstract: Herein described are an assembly, apparatus, and method for lyophilization that utilizes a thermal block made from a conductive material, the block having multiple wells designed and dimensioned to receive containers carrying material to be lyophilized in situ. In preferred embodiments, a vented silicone pad covers the wells and secures the containers therein, and a similarly vented rigid plate in turn secures the silicone pad by fastening it to the thermal block. The assembly can be turned up to 90 degrees resulting in the turning of the containers from an upright position to a horizontal position, a position in which the distance through which sublimation must progress is drastically reduced so as to greatly enhance the efficiency of the lyophilization process.
Abstract: A composition for sustained-release solid dosage form that contains (A) a polyvinyl alcohol-based resin having an average saponification degree of 78 to 96 mol % and an average polymerization degree of 800 or more and (B) a polyhydric phenol compound, preferably tannic acid. A sustained-release tablet having an intended hardness can be produced by a method that includes mixing a granulate prepared from a composition containing (A) a polyvinyl alcohol-based resin powder and a pharmaceutical ingredient with a tannic acid powder, and compressing the mixture into a tablet.
Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.
Type:
Application
Filed:
September 11, 2023
Publication date:
January 4, 2024
Applicant:
Fertin Pharma A/S
Inventors:
Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen
Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
Type:
Application
Filed:
June 12, 2023
Publication date:
January 4, 2024
Applicants:
Tillotts Pharma AG, University College London
Inventors:
Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER
Abstract: An oxygen capsule preparation method includes the following steps: performing three-stage separation on deodorized cocoa butter; then mixing negative oxygen ions with deodorized cocoa butter liquid obtained after the three-stage separation; storing ionic oxygen in the deodorized cocoa butter liquid; and finally filling the deodorized cocoa butter liquid treated by the negative oxygen ions into a capsule shell to be prepared into the capsule, thereby obtaining the oxygen capsule. The oxygen capsule provided by the present disclosure is high in oxygen content, has a good oxygen supplementation effect, and has a good prevention or treatment or adjuvant treatment effect on various chronic non-infectious diseases (such as hypertension, gout, gastric ulcer and anxiety disorder), systemic lupus erythematosus and altitude stress.
Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.
Type:
Application
Filed:
September 18, 2023
Publication date:
January 4, 2024
Applicant:
The New Zealand Institute for Plant and Food Research Limited
Inventors:
John Ronald INGRAM, Edward George WALKER
Abstract: Provided herein are dry powder antiviral compositions, each comprising a microparticle of a pharmaceutically acceptable excipient and nanoparticles of an antiviral, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a viral infection.
Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
Type:
Application
Filed:
June 20, 2023
Publication date:
January 4, 2024
Inventors:
Jan-Otto Carlsson, Anders Johansson, Marten Rooth
Abstract: The invention relates to the field of pharmaceutical compositions comprising proteins as therapeutic agents. More particularly, it is directed to hot melt extrusion-produced antibody-containing filaments, implantable drug delivery devices made from these filaments and to methods of producing such filaments and devices. The hot melt extrusion-produced antibody-containing filaments and the devices obtained from the filaments according to the invention allow the delivery of the antibody over a certain period of time.
Type:
Application
Filed:
November 29, 2021
Publication date:
January 4, 2024
Inventors:
SARAH MARQUETTE, JONATHAN ELEUTHÈRE MAURICE GOOLE, EMERIC CARLIER
Abstract: An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.
Type:
Application
Filed:
September 18, 2023
Publication date:
January 4, 2024
Inventors:
David James ENSCORE, Frank Tagliaferri, Steven Paul Damon, Alan Smith, Jeffrey C. Gaulding
Abstract: Compositions are provided which include an effective amount of a compound selected from the group consisting of propanediol mononitrate and chloroform for the reduction of oxidative stress, the improvement of the immune system, the provision of healthy cartilage, as well as the alleviation of pain in ruminants.
Type:
Application
Filed:
September 19, 2023
Publication date:
January 4, 2024
Inventors:
Chris MC SWEENEY, Gonzalo MARTINEZ FERNANDEZ, Stuart Edward DENMAN, Horst Joachim Paul Peter SCHIRRA
Abstract: The present invention provides a high-dose oral pharmaceutical composition and high drug loading of isotretinoin with low fill-weight, and smaller size capsules, and methods of preparation and use thereof.
Type:
Application
Filed:
June 27, 2023
Publication date:
January 4, 2024
Inventors:
Ashish Anvekar, Nagaprasad Vishnubhotla, Arun Jana
Abstract: Provided is an agent or a food composition capable of decreasing a neutrophil-to-lymphocyte ratio. An agent for decreasing a neutrophil-to-lymphocyte ratio in blood contains a curcumin as an active ingredient.
Type:
Application
Filed:
November 12, 2021
Publication date:
January 4, 2024
Applicants:
THERABIOPHARMA INC., NATIONAL HOSPITAL ORGANIZATION
Abstract: Radiation therapy or chemotherapy may cause oral mucositis. Compositions and methods are disclosed here which prevent and/or treat oral mucositis caused by radiation therapy or chemotherapy. The compositions are also effective in treating a number of skin disorders.
Type:
Application
Filed:
September 12, 2023
Publication date:
January 4, 2024
Inventors:
Brooks Michael Hybertson, Joe Milton McCord
Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.
Abstract: Compounds and methods of scavenging bifunctional electrophiles and reducing the occurrence of lysyl-levuglandin adducts in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: wherein the variables are defined herein.
Type:
Application
Filed:
July 10, 2023
Publication date:
January 4, 2024
Inventors:
Keith T. Wilson, John A. Oates, Olivier Boutaud, Venkataraman Amarnath, Erica J. Carrier, Alain P. Gobert
Abstract: Pharmaceutical compositions of tramadol and pregabalin, or a pharmaceutically acceptable salt thereof, for the treatment of neuropathic pain. Besides offering an analgesic effect and a decrease of adverse events due to the reduced dose of one or both compounds, it has an improved stability, thus maintaining the dissolution and bioavailability of the composition to be administered. The composition manages to overcome the technological difficulty of having two humidity- and light-sensitive drugs in a dispensing medium that does not affect their absorption by means of a water-free process and a light protection coating without affecting the release of both drugs.
Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.
Type:
Application
Filed:
July 5, 2023
Publication date:
January 4, 2024
Inventors:
Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
Abstract: This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 ?m to about 100 ?m. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.
Abstract: An anti-histamine semi-solid chewable gel composition, comprising an active pharmaceutical ingredient (API) composition comprising an antihistamine, a gelling composition in a sufficient amount to provide a cohesive gelled product, a binding composition comprising a sugar, a sugar alcohol, and a water-soluble polymer stabilizer, wherein the polymer stabilizer comprises a polymer of monosaccharide monomers, and wherein the polymer comprises from about 5 to about 500 monosaccharide monomers, wherein the semi-solid chewable gel composition is substantially free of glucose, sucrose, and fructose.
Abstract: The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Type:
Application
Filed:
August 2, 2023
Publication date:
January 4, 2024
Inventors:
Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd SHEARER
Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.
Type:
Application
Filed:
June 30, 2022
Publication date:
January 4, 2024
Applicant:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: An improved, immediate-release pharmaceutical composition against respiratory diseases and acute upper respiratory tract infections (IAVRS) with a stable bioavailability and includes an analgesic, such as ibuprofen; an antihistamine, such as loratadine; and one or more excipients, such as suspending agents, solubilizers, co-solvents, sweeteners or flavorings, colorants, preservatives or antimicrobials, and solvents. The manufacturing process of the composition manages to overcome the technological complexity of having both drugs in liquid form while preserving their physicochemical properties.
Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include beta-hydroxybutyrate (BHB), analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions, such as citrate. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions. Certain formulations enable convenient administration of the beneficial combination product in powdered form for mixing with liquid. Such formulations can be salt-balanced, and may be free of sodium and/or silicates, and are well tolerated. The formulations may be provided in a container and measuring implement to enable convenient measurement of dosages.
Type:
Application
Filed:
August 4, 2023
Publication date:
January 4, 2024
Applicants:
The Regents of the University of California, Augusta University Research Institute, Inc.
Inventors:
Thomas Weimbs, Jacob Torres, Muthusamy Thangaraju
Abstract: This invention teaches a class of fluorinated benzensulfonamides of general structure I, as shown: which are useful for inhibiting protein amyloid aggregation. The compounds taught can be used in pharmaceutical compositions in effective amounts to treat illnesses that result from protein amyloid aggregation.
Type:
Application
Filed:
September 20, 2022
Publication date:
January 4, 2024
Inventors:
Daumantas Matulis, Andrius Sakalauskas, Virginija Dudutiene, Mantas Zvirblis, Mantas Ziaunys, Vytautas Smirnovas
Abstract: A composition for use in a therapeutic method of treatment or prevention of hyperuricaemia, gout and/or renal impairment, said composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B) N-acetyl cysteine, cysteine and/or cystine; C) optionally carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N 6,N6,N6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide riboside, quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate.
Type:
Application
Filed:
November 16, 2021
Publication date:
January 4, 2024
Inventors:
Adil Mardinoglu, Jan Borén, Mathias Uhlén
Abstract: The invention relates to new use of hydroxystearic acid for inducing secretion of anti-microbial peptides (AMPs) when applied on an external surface of the human body. It also relates to an antimicrobial composition comprising a combination of hydroxystearic acid and antimicrobial peptides or antimicrobial lipids or mixtures thereof. This has application in improving the immunity of skin, scalp and oral cavity against attack by microorganisms.
Abstract: Provided is DHA, or a composition comprising DHA, for use in treatment of a biofilm in a subject and for use in treatment of a disease or infection associated or caused by a biofilm in a subject.
Type:
Application
Filed:
October 30, 2021
Publication date:
January 4, 2024
Applicant:
TECHNOLOGICAL UNIVERSITY DUBLIN
Inventors:
Gordon COOKE, Emma CARAHER, Jonathan BRADY
Abstract: ?-3 polyunsaturated fatty acids for use in the prevention and treatment of male infertility in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments for the treatment of neoplasms. ?-3 polyunsaturated fatty acids are selected from the group consisting of 20:5 ?-3 eicosapentaenoic acid, 18:3 ?-3 ?-linolenic acid, 22:6 ?-3 docosahexaenoic acid, and 22:5 ?-3 docosapentaenoic acid. Preferably, ?-3 polyunsaturated fatty acid is 20:5 ?-3 eicosapentaenoic acid.
Type:
Application
Filed:
November 9, 2021
Publication date:
January 4, 2024
Inventors:
Giovanni LUCA, Riccardo CALAFIORE, Alba VECCHINI, Francesca MANCUSO, Iva ARATO, Veronica CECCARELLI
Abstract: Methods of treating cancer comprising the use of combinations of a retinoid, e.g., all-trans retinoic acid (ATRA), and radiotherapy are described. The administration of a retinoid can enhance the effect of radiotherapy, including enhancing fractionated, low-dose radiotherapy. Use of the combination increases tumor necrosis factor alpha (TNF-?)- and inducible nitric oxide synthase (iNOS)-producing inflammatory macrophages in local (radiated) and distal (non-radiated) tumors. The methods can optionally further involve the use of checkpoint blockade immunotherapy.
Type:
Application
Filed:
June 5, 2023
Publication date:
January 4, 2024
Inventors:
Wenbin Lin, Ralph R. Weichselbaum, Hua Liang, Yingying Li
Abstract: A method for treating lung cancer is provided. The method includes administering a pharmaceutical composition including a diarylheptanoid compound or a pharmaceutically acceptable salt thereof to inhibit the growth of lung cancer cells. The diarylheptanoid compound has a structure shown in Formula (I), in which symbols in Formula (I) are as defined in the description.
Abstract: Compositions and methods for treating alopecia, particularly chemotherapy-induced alopecia, using oxidizers or oxidants, pro-oxidant compounds, or activators of P53. Compositions comprising organic peroxides such as, cumene hydroperoxide, tert-Butyl hydroperoxide (t-BHP), hydrogen peroxide, benzoyl peroxide are preferred. Compositions may be applied subcutaneously, percutaneously, or topically. Most preferably, the compositions are applied to a treatment area prior to a round of chemotherapy to prevent or reduce hair loss in the treatment area.
Abstract: Composition comprising a combination of oleuropein or metabolite thereof and quercetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be administered to an individual in need thereof for improving a physiological state linked to metabolic fatigue in one or more cells, (ii) increasing mitochondrial energy and mitochondrial calcium uptake in one or more cells, and (iii) increasing antioxidant capacity, reducing oxidative stress and/or enhancing mitochondrial function, (iv) treating or preventing a calcium deficiency/depletion disorder in an individual. Additionally, or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.
Abstract: The present invention relates to novel physiological cooling agents, cooling agent mixtures containing said novel agents, mixtures of said cooling agents with flavourings, the use of said cooling agents, and articles and final consumer preparations containing said physiological cooling agents or cooling agent mixtures.
Type:
Application
Filed:
November 17, 2021
Publication date:
January 4, 2024
Inventors:
Judith Minakar, Benoit Join, Michael Backes, Saskia Hupe, Dominik Stuhlmann, Joachim Hans, Gabriela Matuszko
Abstract: An object of the present invention is to provide a novel agent capable of activating SIRT6. A sirtuin 6 activator containing a urolithin as an active ingredient.
Type:
Application
Filed:
November 26, 2021
Publication date:
January 4, 2024
Applicants:
DAICEL CORPORATION, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
Abstract: Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose. Further described herein are uses wherein the CB1 inhibitor is ANEB-001. Further described herein are treatments with a CB1 inhibitor for THC or synthetic cannabinoid overdose.
Type:
Application
Filed:
November 17, 2021
Publication date:
January 4, 2024
Inventors:
Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER
Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient; and one of or a combination of methacrylic acid copolymer, or a cellulose derivative wherein the active pharmaceutical ingredient is a dengue viral replication inhibitor. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of prevention and/or treatment and/or inhibition of viral replication are also described.
Type:
Application
Filed:
November 3, 2021
Publication date:
January 4, 2024
Inventors:
Donghua Zhu, Kristof Leonard Kimpe, Sune Klint Andersen, Matthieu Jean M. Ravelingien, Ivan Henri M. Somers
Abstract: The present invention relates to a pharmaceutical composition comprising crystalline particles comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof comprising the compound of Formula 2 below in an amount of 0.2 wt. % or less. The crystalline particles according to the present invention, have a size, shape and distribution that improve uniformity and flowability as well as being optimized for input into the preparation process of the finished drug product, thereby increasing the content uniformity in the preparation process of the finished product and minimizing breakage during compressing into tablets, and thus can be used as a raw material pharmaceutical product suitable for the preparation process of the finished drug product.
Type:
Application
Filed:
November 2, 2021
Publication date:
January 4, 2024
Applicant:
LG CHEM, LTD.
Inventors:
Seok Ju LEE, Ah Byeol PARK, Hui Rak JEONG, Jinok HAM, Doosup SHIN